Ocular Therapeutix, Inc.

Stage 3 · Topping · week 3

As of Oct 22, 2026, Ocular Therapeutix is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $6.61, 59.0% below its 52-week high and below its 200-day average, which is falling.

$6.61

+1.50% today

$1.5B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is OCUL early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 24w

S2 14w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 17w → S1 7w → S2 12w → S3 10w → S2 24w → S3 8w → S4 11w → S1 10w → S2 14w → S3 7w → S2 7w → S3 3w → S4 10w → S1 3w → S4 3w → S1 6w → S4 2w → S1 5w → S2 2w → S3 2w current

Total tracked: 165 weeks across 21 stage runs.

OCUL among Biotechnology331st of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…331	OCULOcular Therapeutix, Inc.	Stage 3 · wk 3	26	−33.9%

vs 52W High

-59.0%

$6.29 lo$16.11 hi

59.0% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 3

1w13w26w

Week 3, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-28.5%

200 DMA: $9.24 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.65x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-33.9%

-22.3%

-31.1%

YTD

-44.1%

-43.8%

Scan Membership

Breakout Watch

Latest: 2024-07-15

7 appearances in last 60 days. First seen: 2018-10-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 3 · Vol 0.65x

2026-10-21S3

Wk 3 · Vol 0.63x

2026-10-20S3

Wk 3 · Vol 0.80x

2026-10-19S3

Wk 2 · Vol 2.64x

2026-10-16S3

Wk 2 · Vol 0.88x

2026-10-15S3

Wk 2 · Vol 1.05x

2026-10-14S3

Wk 2 · Vol 0.71x

2026-10-13S3

Wk 2 · Vol 1.03x

2026-10-12S3

Wk 1 · Vol 1.19x

2026-10-09S3

Wk 1 · Vol 0.85x

2026-10-08S3

Wk 1 · Vol 1.28x

2026-10-07S3

Wk 1 · Vol 0.97x

Moving averages & range

50 DMA

$9.28

200 DMA

$9.24

52W High

$16.11

52W Low

$6.29

5D Low

$6.29

Resistance levels (recent highs)

20d High

$9.65

60d High

$11.73

120d High

$11.73

250d High

$16.11

Next resistance

+46.0%

to 20d High

ROE

-73.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.8

Ocular Therapeutix: quick answers

What stage is Ocular Therapeutix in?

As of Oct 22, 2026, Ocular Therapeutix (OCUL) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Ocular Therapeutix in an uptrend?

Its uptrend has stalled. Ocular Therapeutix is in Stage 3, the topping phase that follows an advance. It trades 28.5% below its 200-day average, which is falling.

How far is Ocular Therapeutix from its 52-week high?

Ocular Therapeutix closed at $6.61 on Oct 22, 2026, 59.0% below its 52-week high of $16.11. Its 52-week low is $6.29.

How has Ocular Therapeutix performed over the past year?

As of Oct 22, 2026, Ocular Therapeutix is down 43.8% over the past year and down 44.1% so far in 2026.

Which sector and industry is Ocular Therapeutix in?

Ocular Therapeutix is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.